タナカ　ジユンジ   TANAKA Junji   田中　淳司    所属   その他 その他    職種   非常勤嘱託
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Occurrence of adverse events caused by valganciclovir as pre-emptive therapy for cytomegalovirus infection after allogeneic stem cell transplantation is reduced by low-dose administration.
掲載誌名	正式名：Transplant infectious disease : an official journal of the Transplantation Society 略　 称：Transpl Infect Dis ISSNコード：(1399-3062)1398-2273(Linking)
掲載区分	国外
巻・号・頁	17(6),pp.810-815
著者・共著者	Takahata M†, Hashino S, Nishio M, Sugita J, Shigematsu A, Onozawa M, Fujimoto K, Endo T, Kondo T, Tanaka J, Imamura M, Teshima T
発行年月	2015/12
概要	Low-dose VGCV was not inferior in clinical efficacy, including clearance rate of CMV antigenemia and incidence of consequent CMV disease, to standard-dose VGCV as was previously reported. Initial low-dose VGCV for pre-emptive CMV therapy markedly reduces hematologic toxicity and has clinical efficacy equivalent to that of standard-dose VGCV. It is therefore reasonable for patients, except for noticeably overweight patients, to be given initial low-dose VGCV.
DOI	10.1111/tid.12456
PMID	26354293